Akira S, Takeda K. (2004). Toll-like receptor signalling. Nat Rev Immunol 4: 499–511.
Akira S, Takeda K, Kaisho T. (2001). Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2: 675–680.
Balkwill F, Charles KA, Mantovani A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211–217.
Ben-Baruch A. (2006). Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 16: 38–52.
Bingle L, Brown NJ, Lewis CE. (2002). The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196: 254–265.
de Vos AF, Pater JM, van den Pangaart PS, de Kruif MD, van ‘t Veer C, van der Poll T. (2009). In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLR ligands. J Immunol 183: 533–542.
del Fresno C, Otero K, Gomez-Garcia L, Gonzalez-Leon MC, Soler-Ranger L, Fuentes-Prior P et al. (2005). Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J Immunol 174: 3032–3040.
Deng JC, Cheng G, Newstead MW, Zeng X, Kobayashi K, Flavell RA et al. (2006). Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M. J Clin Invest 116: 2532–2542.
Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA et al. (2005). Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97: 1407–1427.
Elgert KD, Alleva DG, Mullins DW. (1998). Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 64: 275–290.
Elliott RL, Blobe GC. (2005). Role of transforming growth factor Beta in human cancer. J Clin Oncol 23: 2078–2093.
Gordon S. (2003). Alternative activation of macrophages. Nat Rev Immunol 3: 23–35.
Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K. (2001). Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 91: 964–971.
Jacobsen SE, Keller JR, Ruscetti FW, Kondaiah P, Roberts AB, Falk LA. (1991). Bidirectional effects of transforming growth factor beta (TGF-beta) on colony-stimulating factor-induced human myelopoiesis in vitro: differential effects of distinct TGF-beta isoforms. Blood 78: 2239–2247.
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. (2005). Cancer statistics, 2005. CA Cancer J Clin 55: 10–30.
Johnson SK, Kerr KM, Chapman AD, Kennedy MM, King G, Cockburn JS et al. (2000). Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer 27: 27–35.
Kim WS, Park C, Jung YS, Kim HS, Han J, Park CH et al. (1999). Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung. Anticancer Res 19: 301–306.
Kobayashi K, Hernandez LD, Galan JE, Janeway Jr CA, Medzhitov R, Flavell RA. (2002). IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110: 191–202.
Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS. (1999). Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 86: 1712–1719.
Letterio JJ, Roberts AB. (1998). Regulation of immune responses by TGF-beta. Annu Rev Immunol 16: 137–161.
Lewis CE, Pollard JW. (2006). Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605–612.
Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. (2006). Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24: 99–146.
Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. (1992). The origin and function of tumor-associated macrophages. Immunol Today 13: 265–270.
Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. (2002). Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549–555.
McCartney-Francis N, Jin W, Wahl SM. (2004). Aberrant Toll receptor expression and endotoxin hypersensitivity in mice lacking a functional TGF-beta 1 signaling pathway. J Immunol 172: 3814–3821.
Moustakas A, Heldin CH. (2003). Ecsit-ement on the crossroads of Toll and BMP signal transduction. Genes Dev 17: 2855–2859.
Mytar B, Woloszyn M, Szatanek R, Baj-Krzyworzeka M, Siedlar M, Ruggiero I et al. (2003). Tumor cell-induced deactivation of human monocytes. J Leukoc Biol 74: 1094–1101.
Naiki Y, Michelsen KS, Zhang W, Chen S, Doherty TM, Arditi M. (2005). Transforming growth factor-beta differentially inhibits MyD88-dependent, but not TRAM- and TRIF-dependent, lipopolysaccharide-induced TLR4 signaling. J Biol Chem 280: 5491–5495.
Pan H, Ding E, Hu M, Lagoo AS, Datto MB, Lagoo-Deenadayalan SA. (2010). SMAD4 is required for development of maximal endotoxin tolerance. J Immunol 184: 5502–5509.
Pardoll D. (2003). Does the immune system see tumors as foreign or self? Annu Rev Immunol 21: 807–839.
Pollard JW. (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71–78.
Reddy RC, Keshamouni VG, Jaigirdar SH, Zeng X, Leff T, Thannickal VJ et al. (2004). Deactivation of murine alveolar macrophages by peroxisome proliferator-activated receptor-gamma ligands. Am J Physiol Lung Cell Mol Physiol 286: L613–L619.
Rosati O, Martin MU. (2002). Identification and characterization of murine IRAK-M. Biochem Biophys Res Commun 293: 1472–1477.
Scagliotti G, Novello S. (2003). Adjuvant chemotherapy after complete resection for early stage NSCLC. Lung Cancer 42(Suppl 1): S47–S51.
Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. (2001). Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2: 947–950.
Seya T, Akazawa T, Uehori J, Matsumoto M, Azuma I, Toyoshima K. (2003). Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res 23: 4369–4376.
Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL et al. (2008). Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14: 822–827.
Souquet PJ, Geriniere L. (2001). The role of chemotherapy in early stage of non-small cell lung cancer. Lung Cancer 34(Suppl 2): S155–S158.
Toonkel RL, Borczuk AC, Powell CA. (2010). TGF-beta signaling pathway in lung adenocarcinoma invasion. J Thorac Oncol 5: 153–157.
van ‘t Veer C, van den Pangaart PS, van Zoelen MA, de Kruif M, Birjmohun RS, Stroes ES et al. (2007). Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J Immunol 179: 7110–7120.
Wesche H, Gao X, Li X, Kirschning CJ, Stark GR, Cao Z. (1999). IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. J Biol Chem 274: 19403–19410.
Xiao C, Shim JH, Kluppel M, Zhang SS, Dong C, Flavell RA et al. (2003). Ecsit is required for Bmp signaling and mesoderm formation during mouse embryogenesis. Genes Dev 17: 2933–2949.
Xie Q, Gan L, Wang J, Wilson I, Li L. (2007). Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth. Mol Immunol 44: 3453–3461.
Yamaguchi H, Pixley F, Condeelis J. (2006). Invadopodia and podosomes in tumor invasion. Eur J Cell Biol 85: 213–218.